| A systematic review and meta-analysis of vitamin D and calcium in preventing osteoporotic fractures A Eleni, P Panagiotis Clinical rheumatology 39 (12), 3571-3579, 2020 | 36 | 2020 |
| Tendering for pharmaceuticals as a reimbursement tool in the Cyprus Public Health Sector P Petrou, MA Talias Health Policy and Technology 3 (3), 167-175, 2014 | 33 | 2014 |
| Is it a Chimera? A systematic review of the economic evaluations of CAR-T cell therapy P Petrou Expert review of pharmacoeconomics & outcomes research 19 (5), 529-536, 2019 | 31 | 2019 |
| Cyprus in crisis: recent changes in the pharmaceutical market and options for further reforms without sacrificing access to or quality of treatment P Petrou, S Vandoros Health Policy 119 (5), 563-568, 2015 | 31 | 2015 |
| Single-payer or a multipayer health system: a systematic literature review P Petrou, G Samoutis, C Lionis Public health 163, 141-152, 2018 | 29 | 2018 |
| An interrupted time-series analysis to assess impact of introduction of co-payment on emergency room visits in Cyprus P Petrou Applied health economics and health policy 13, 515-523, 2015 | 25 | 2015 |
| Healthcare reforms in Cyprus 2013–2017: Does the crisis mark the end of the healthcare sector as we know it? P Petrou, S Vandoros Health Policy 122 (2), 75-80, 2018 | 24 | 2018 |
| Long-term effect of tendering on prices of branded pharmaceutical products P Petrou Health Policy and Technology 5 (1), 40-46, 2016 | 23 | 2016 |
| A framework for applying health technology assessment in cyprus: thoughts, success stories, and recommendations P Petrou, MA Talias Value in health regional issues 2 (2), 273-278, 2013 | 21 | 2013 |
| Crisis as a serendipity for change in Cyprus' healthcare services P Petrou Journal of Medical Economics 18 (10), 805-807, 2015 | 19 | 2015 |
| Cost–effectiveness of sorafenib compared to best supportive care in second line renal cell cancer from a payer perspective in Cyprus P Petrou, MA Talias Expert review of pharmacoeconomics & outcomes research 14 (1), 131-138, 2014 | 19 | 2014 |
| Failed attempts to reduce inappropriate laboratory utilization in an emergency department setting in Cyprus: lessons learned P Petrou The Journal of Emergency Medicine 50 (3), 510-517, 2016 | 18 | 2016 |
| Financial crisis as a reform mediator in Cyprus’s health services P Petrou Eurohealth 20 (4), 35-38, 2014 | 18 | 2014 |
| A pilot study to assess feasibility of value based pricing in Cyprus through pharmacoeconomic modelling and assessment of its operational framework: sorafenib for second line … P Petrou, MA Talias Cost Effectiveness and Resource Allocation 12, 1-11, 2014 | 15 | 2014 |
| Price determinants of the tendering process for pharmaceuticals in the Cyprus market P Petrou, MA Talias Value in Health Regional Issues 7, 67-73, 2015 | 14 | 2015 |
| Pharmacoeconomics in the years of crisis: a solution or just a resolution? A Cyprus perspective P Petrou Expert review of pharmacoeconomics & outcomes research 14 (5), 627-636, 2014 | 14 | 2014 |
| The 2019 introduction of the new National Healthcare System in Cyprus P Petrou Health Policy 125 (3), 284-289, 2021 | 13 | 2021 |
| Burden of non-communicable disease studies in Europe: a systematic review of data sources and methodological choices P Charalampous, V Gorasso, D Plass, SM Pires, E Von Der Lippe, ... European Journal of Public Health 32 (2), 289-296, 2022 | 12 | 2022 |
| Implementing shared-decision-making for diabetes care across country settings: what really matters to people? M Tinelli, P Petrou, G Samoutis, V Traynor, G Olympios, A McGuire Health Policy 121 (7), 786-792, 2017 | 12 | 2017 |
| The power of r–pharmaceutical sales decomposition in Cyprus public healthcare sector and determinants of drug expenditure evolution: any lessons learned? P Petrou Expert review of pharmacoeconomics & outcomes research 14 (2), 289-300, 2014 | 11 | 2014 |
